Nationality : Iran
Position : Chair and Chief Executive Officer for Seer; Former Professor at Harvard Medical School and director of the Center for Nanomedicine at Brigham and Women’s Hospital, USA
Field of study : Nanomedicine, Drug Delivery, Biomaterials, Targeted Therapy
Get in touch :
Prof. Omid Farokhzad is the Chair and Chief Executive Officer for Seer (NASDAQ: SEER). Previously, he was Professor at Harvard Medical School and directed the Center for Nanomedicine at Brigham and Women’s Hospital. He has authored over 185 papers and is an inventor of over 200 issued and pending patents. His work has been cited ~85,000 with an h-index of 121. Farokhzad previously founded BIND Therapeutics (NASDAQ: BIND, acquired by Pfizer), Selecta Biosciences (NASDAQ: SELB), and Tarveda Therapeutics. He is a 2018 Fellow of the National Academy of Inventors. He is a recipient of the 2016 Ellis Island Medal of Honor and the 2014 Golden Door Award from the International Institute of New England, for his scientific, societal, and economic contributions to America as an immigrant; the 2013 RUSNANOPRIZE for his work on nanomaterial surface modification; and the 2012 Ernst & Young New England Entrepreneur of the Year award. He received his M.D. and M.A. from Boston University and his M.B.A. from MIT Sloan School of Management. He completed his post-graduate clinical training in Anesthesiology and Pain Medicine at Brigham and Women’s Hospital, and his post-doctoral training at the laboratory of Professor Robert Langer at MIT.